Market Announcements 2018
DECEMBER 2018
20 December 2018 – PAT-DX1 Suppresses Breast Cancer Brain Metastases
NOVEMBER 2018
22 November 2018 – Results of Annual General Meeting
22 November 2018 – Chairman’s Address and CEO Presentation
OCTOBER 2018
25 October 2018 – Settlement of Manufacturing Claims
23 October 2018 – Notice of Annual General Meeting/ Proxy Form
8 October 2018 – Patrys and Yale Awarded Grant
4 October 2018 – PAT-DX1 Clinical Target Indications Confirmed
SEPTEMBER 2018
13 September 2018 – PAB Business Review – 30 June 2018
AUGUST 2018
28 August 2018 – Patrys and WEHI Awarded Grant
1 August 2018 – Patent Granted for Pre-clinical IgM Candidate PAT-LM1
JULY 2018
5 July 2018 – Preliminary PAT-DX1 Pharmacokinetics
3 July 2018 – China and Japan Both Grant Patents for Deoxymab 3E10
JUNE 2018
12 June 2018 – Corporate Overview
MAY 2018
31 May 2018 – PAT-DX1 Targets and Kills Brain Cancer Stem Cells
21 May 2018 – Patrys Increases Capital Raising to $4.6 Million
17 May 2018 – New Pre-Clinical Collaboration on PAT-DX1
16 May 2018 – Announcement of $3.5 Million Share Placement
APRIL 2018
17 April 2018 – Patrys Presents at AACR Conference
MARCH 2018
19 March 2018 – PAT-DX1 Improves Survival in Animal Model of Glioblastoma
FEBRUARY 2018
28 February 2018 – PAT-DX1 Crosses the Blood Brain Barrier to Reduce Tumor Size
16 February 2018 – Patrys Successfully Completes Rights Issue – Raises $2.4M
JANUARY 2018
30 January 2018 – Publication and Patent Filing for Humanized Version of Deoxymab 3E10
29 January 2018 – PAT-DX1-NP Localizes to Lymph Node Metastases
29 January 2018 – PAT-DX1 Targets Delivery of Nanoparticles to Breast Cancer
